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I wish to thank Ric Price and col­
leagues1 for highlighting the under­
studied chloroquine resistance in 
Plasmodium vivax in their systematic 
review and meta­analysis. However, I 
would question their study inclusion 
criteria: the primary outcome was “the 
risk of recurrent P vivax parasitaemia 
at day 28” when table 1 lists four 
studies with follow­up periods of less 
than 27 days. I would also suggest 
that it seems a shame that two 
author­reviewers, independently, did 
not extract and analyse the studies 
and data for inclusion, as seems 
standard practice for good systematic 
reviews.2 Lastly, although the paper 
underlines the extent and importance 
of chloroquine­resistant P vivax, I am 
none the wiser on what management 
I should offer in practice to patients 
from different areas given the 
prevalence of resistance.
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